Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, ...
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy -
Source: eagletribune.com